Physician profile
John Joseph Ryan
NPI 1902071673
$1,389,152.96
in general payments reported to CMS, 2019-2025
24 companies · $320K in 2025
The $320K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $55K · 2021: $95K · 2022: $299K · 2023: $244K · 2024: $364K · 2025: $320K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $645K · Travel and Lodging: $137K · Honoraria: $68K · Consulting Fee: $58K · Food and Beverage: $19K · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $645,356.00 |
| Travel and Lodging | $137,364.07 |
| Honoraria | $67,525.00 |
| Consulting Fee | $58,462.92 |
| Food and Beverage | $19,223.67 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $522,656.63 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| United Therapeutics Corporation | $305,949.48 | 2021-2025 | Tyvaso, Remodulin, Orenitram |
| Merck Sharp & Dohme LLC | $217,895.79 | 2021-2025 | Winrevair, Verquvo, Bridion |
| Bayer Healthcare Pharmaceuticals INC. | $101,433.13 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $74,175.88 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, Ltd. | $67,213.92 | 2022-2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $44,827.73 | 2023-2024 | Inpefa |
| Scpharmaceuticals INC. | $31,974.02 | 2025 | |
| Inari Medical, INC. | $17,110.38 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Vertex Pharmaceuticals Incorporated | $4,582.84 | 2021-2023 | |
| Medtronic, INC. | $472.50 | 2021 | |
| Ge Healthcare | $160.00 | 2021 | |
| Penumbra, INC. | $127.27 | 2023 | Indigo System |
| Insmed, INC. | $122.91 | 2025 | Arikayce |
| Impulse Dynamics (USA) INC. | $119.47 | 2024 | Optimizer |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $109.86 | 2025 | |
| Sandoz INC. | $104.11 | 2023-2025 | Treprostinil |
| Astrazeneca Pharmaceuticals Lp | $62.48 | 2022-2023 | Brilinta |
| Novo Nordisk INC | $34.86 | 2025 | Wegovy |
| Liquidia Technologies, INC. | $19.70 | 2025 | Yutrepia |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.